Case report: Patient presents with KIT-negative SM and acute myeloid leukemia
The case highlights the challenges of diagnosing and treating both KIT-negative SM and SM with an associated hematologic neoplasm (SM-AHN).
The case highlights the challenges of diagnosing and treating both KIT-negative SM and SM with an associated hematologic neoplasm (SM-AHN).
Patients who test negative for the KIT D816V mutation may need further testing for clonal mast cell diseases such as SM, a study found.
The WHO guidelines provide a standardized framework that helps doctors provide the right care for patients.
Flow-SuperRCA is a new, ultra-sensitive test to detect the D816V KIT mutation in patients with SM and other mast cell conditions.
Drug-induced reactions such as anaphylaxis are possible in patients with SM, but recent data suggests that the risk is relatively low.
A combination of quantitative and laboratory techniques may be used to improve the diagnosis of SM with flow cytometry, a recent study found.
A clinical trial is currently underway to determine the optimal dosage of a novel cancer drug in patients with ISM.
A first-of-its-kind study in Europe identified sources of disease burden as reported by patients with SM and their healthcare providers.
A clinical trial of 16 patients with indolent SM found that sarilumab does not significantly improve quality of life.
A patient who was diagnosed with mast cell leukemia, a rare form of SM, experienced symptom relief with methylprednisolone treatment.